MRI引导的超局灶 salvage 高剂量率近距离放疗治疗局限性放射性复发前列腺癌:50例患者更新结果
该研究分析了前50例接受超局灶 salvage 高剂量率近距离放疗(HDR-BT)的放射性复发前列腺癌患者的前瞻性数据,方案为单次19 Gy,中位随访31个月。结果显示3级泌尿生殖毒性2%、无3级胃肠道毒性、22%新发3级勃起功能障碍,2.5年生化无病生存率51%、无转移生存率75%、无ADT生存率90%、总生存率98%。
要点
- 超局灶 salvage HDR-BT(1×19 Gy)在精选患者中安全性可接受,3级泌尿生殖毒性仅2%。
- 2.5年生化无病生存率51%,无ADT生存率90%,可有效推迟雄激素剥夺治疗。
- salvage前PSA、CTV大小和≥T3分期与生化失败显著相关,高危患者2.5年生化无病生存率仅25%。
核心结论
- MRI引导的超局灶 salvage HDR-BT在早期阶段似乎是安全的 salvage 治疗选择,在精选患者中生化控制可接受,并可能有效推迟雄激素剥夺治疗。
研究设计与样本
- 前瞻性收集前50例接受治疗患者的数据,采用3T多参数MRI、18F-胆碱或68Ga-PSMA PET/CT及系统或肿瘤靶向活检评估疾病状态。
- 超局灶 salvage HDR-BT(1×19 Gy)在融合经直肠超声/MRI引导下植入临床靶体积(CTV:大体肿瘤体积+5 mm margin)。
主要发现
- 中位随访31个月,CTV D95%中位值为18.8 Gy。
- 观察到2%的3级泌尿生殖毒性、无3级胃肠道毒性、22%新发3级勃起功能障碍。
- 13例自报治疗前勃起功能正常(IIEF>17)的患者中5例(38%)保持勃起功能。
- 31个生活质量条目中仅6个报告临床相关恶化,且无统计学显著性。
- 26例发生生化失败(nadir+2),前列腺内复发中73%为野内复发。
关键数值与推荐
- 2.5年生化无病生存率为51%(95%CI 37%-69%),无转移生存率为75%(64%-89%),无ADT生存率为90%(82%-99%),总生存率为98%(94%-100%)。
- salvage前PSA、CTV大小和分期≥T3与生化失败显著相关。
- 较高危患者(分期≥T3、PSA≥10或PSA倍增时间≤9个月)2.5年生化无病生存率为25%,较低危患者为71%。
临床怎么用
- 对于经过严格筛选的局限性放射性复发前列腺癌患者,可考虑MRI引导的超局灶 salvage HDR-BT作为推迟ADT的治疗选择。
- 治疗前应评估PSA、CTV大小和分期,高危患者(≥T3、PSA≥10或PSA倍增时间≤9个月)生化控制较差,需谨慎选择。
局限性
- 样本量较小(50例),随访时间较短(中位31个月),结论需更长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most patients with local prostate cancer recurrence after radiation therapy undergo palliative androgen deprivation therapy because whole-gland salvage treatments have a high risk of severe toxicity. Focal treatment reduces this risk while offering a second opportunity for cure. We report updated outcomes of ultrafocal salvage high-dose-rate brachytherapy (HDR-BT). METHODS AND MATERIALS: Prospectively collected data from the first 50 treated patients were analyzed. Disease status was assessed by 3T multiparametric magnetic resonance imaging (MRI), 18F-Choline or 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography, and systematic or tumor-targeted biopsies. Ultrafocal salvage HDR-BT (1 × 19 Gy) was performed by implanting the clinical target volume (CTV: gross tumor volume + 5 mm margin) under fused transrectal ultrasound/MRI guidance. Follow-up included toxicity grading (using Common Terminology Criteria for Adverse Events 4.0), quality of life assessment, and prostate-specific antigen (PSA) testing. RESULTS: Median follow-up was 31 months. Median CTV D95% was 18.8 Gy. We observed 2% grade 3 genitourinary toxicity, no grade 3 gastrointestinal toxicity, and 22% newly developed grade 3 erectile dysfunction. Five of 13 patients (38%) with self-reported pretreatment potency (International Index of Erectile Function >17) remained potent. Clinically relevant quality of life deterioration was reported for only 6 of 31 items and was not statistically significant. Biochemical failure (nadir + 2) occurred in 26 patients. Among intraprostatic recurrences, 73% were in field. After 2.5 years, biochemical disease-free survival was 51% (95% confidence interval, 37%-69%), metastases-free survival was 75% (64%-89%), androgen deprivation therapy-free survival was 90% (82%-99%), and overall survival was 98% (94%-100%). Presalvage PSA, CTV size, and stage ≥T3 were significantly associated with biochemical failure. Higher-risk patients (stage ≥T3, PSA ≥10, or PSA double time ≤9 months) had 25% biochemical disease-free survival at 2.5 years versus 71% for lower-risk patients. CONCLUSIONS: At this early stage, MRI-guided ultrafocal HDR-BT seems to be a safe salvage treatment option, with acceptable biochemical control in a well-selected group of patients and potential for effectively postponing androgen deprivation therapy.
引用
- van Son MJ, Peters M, Moerland MA, et al. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. Int J Radiat Oncol Biol Phys. 2020. PMID: 32006609. doi:10.1016/j.ijrobp.2020.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。